Author: biocytogen

Webinar: Generation and discovery of high affinity antibodies

April 11, 2022

Our webinar “Generation and discovery of high affinity antibodies” was live on April 27, 2022 at 1PM EDT. In this webinar, we will Introduce Biocytogen’s Antibody Discovery Service capabilities, which includes multiple screening technologies and accommodates antibody discovery needs for multiple species, including human, mouse, and rat. Provide proof-of-concept data supporting the robust capabilities of […]

Read More

Biocytogen Subsidiary Eucure Biopharma Completes First Patient Dosing for Phase I Clinical Trial of YH003 (Anti-CD40 mAb) Triple Combination Therapy

April 6, 2022

BEIJING, April 6, 2022 – Biocytogen subsidiary Eucure Biopharma announced the first patient dosing for a phase I clinical trial (No. YH003005) of YH003 (anti-CD40 monoclonal antibody, mAb) in combination with YH001 (anti-CTLA-4 mAb) and pembrolizumab (anti-PD-1 mAb) in Australia. The study is an open-label, dose-escalation study designed to evaluate the safety, tolerability and efficacy […]

Read More

Biocytogen Expands Global Footprint with the Opening of Biocytogen Europe Innovation Center in Germany

March 28, 2022

Beijing, China and Heidelberg, Germany, March 28, 2022 – Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (hereafter referred to as “Biocytogen”) announced the opening of the Biocytogen Europe Innovation Center (BEIC) in Heidelberg, Germany. Local government representatives, clinical experts, and colleagues and collaborators from multi-national companies made speeches at the opening ceremony. Dr. Vivian Tian, Head of […]

Read More

AACR 2022

March 23, 2022

  Attend the meeting Our Poster Session Talk to us at booth 1043! The AACR Annual Meeting is the focal point of the cancer research community, where scientists, clinicians, other health care professionals, survivors, patients, and advocates gather to share the latest advances in cancer science and medicine. From population science and prevention; to cancer […]

Read More

Experimental Biology 2022

March 23, 2022

                          Attend the meeting Presentation Information Talk to us at booth 830! Experimental Biology (EB) is the annual meeting of five societies that explores the latest research in anatomy, biochemistry and molecular biology, investigative pathology, pharmacology, and physiology. Participants represent scientists from academic […]

Read More

Biocytogen Subsidiary, Eucure Biopharma, Announces the First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia

March 8, 2022

BEIJING, CHINA, March 8, 2022 – Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dosing for a phase I multi-regional clinical trial (MRCT) of YH002 (anti-OX40 monoclonal antibody, mAb) in combination with YH001 (anti-CTLA-4 mAb) (No. YH002004) in Australia. This phase I MRCT will be conducted in Australia and China. The clinical […]

Read More

Webinar: Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice

February 22, 2022

Our webinar “Design and Screening of Bispecific ADCs Discovered in RenLite Common Light Chain Antibody Mice” was live on March 16, 2022 at 11AM EDT. In this webinar, we Introduced Biocytogen’s next-generation fully human bispecific antibody development platform, which has facilitated drug discovery for more than two hundred TAA (tumor associated antigen) targets Analyzed the […]

Read More

Immuno-Oncology 360° 2022 Summit

February 17, 2022

Attend the meeting Agenda Talk to us at booth 4! IO360˚convenes stakeholders from the science and business communities to report on the latest data impacting IO to fight a wider range of cancers.

Read More

Festival of Biologics USA 2022

February 15, 2022

Speaker: Li Hui M.D., Ph.D., Director, Antibody Discovery & RenMice Licensing, Biocytogen Boston Corp Time: 5:10pm PST, March 9th Talk title: Streamlining Therapeutic Antibody Discovery For All Targets Session details: Human antibodies generated from fully human antibody transgenic mice have a higher chance of clinical success due to the in vivo natural selection and affinity […]

Read More

Webinar: Mouse Models to Investigate New Treatments for Inflammatory Disease

January 7, 2022

We’re pleased to continue our new webinar series informing and updating our network of research professionals. We invite you to join us to learn about the latest technological advances at Biocytogen and to engage with our expert scientists! Our webinar “Mouse Models to Investigate New Treatments for Inflammatory Disease” was live on Jan 26, 2022 […]

Read More

Back to top